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Troubles with Biocitizenship? 
 




Genetic and other biotechnologies are starting to impact significantly upon society 
and individuals within it. Rose and Novas draw on an analysis of many patient groups 
to sketch out the broad notion of biocitizenship as a device for describing how the 
empowered and informed individual, group or network can engage with bioscience. In 
this paper, we examine critically the notion of biocitizenship, drawing on both 
sociological fieldwork that grounds the debate in the views of a large and varied 
group of concerned actors. Using work within green politics, we identify 
shortcomings in the concept of biocitizenship as it has so far been explicated. The 
value assumptions lying behind an account of biocitizenship, and its tendency to see 
issues through a reductive lens, are examined. Alternative views of values and goals, 
which may undermine any alleged rights and duties, are explored using interviews and 
other ethnographic data that illustrates the complexity of the terrain. The reductive 
lens of biocitizenship is explored through contrast with the wider scope of concerns 
emanating from various sources, including many within green politics. If such 
complexities are not recognised, there is a danger that a concept of biocitizenship may 
serve to create and amplify inequalities. Problems with identity issues are key: the 
construction of identity is complex and many groups are explicitly rejecting the 
‘biological’ label. We discuss the multiple relations of citizens with the biotech and 
pharmaceutical industries. Arguably, existing inequalities in power relationships, 
exploitation, commodification and ownership patterns are being perpetuated in novel 
ways through the new biosciences. We pose the question of whether it is possible to 




Biotechnology, including genetic technology and information, is having a significant 
and growing impact upon society and individuals. One concept that has been used to 
provide a framework for examining this impact is that of biocitizenship. As explicated 
by Rose and Novas,1 biocitizenship can be seen as one account of the many versions 
of citizenship currently under discussion. Their concept needs to be examined against 
other contemporary citizenship debates. In this paper we examine critically Rose and 
Novas’s notion of biocitizenship and suggest that it covers such complex and 
contested ground that its usefulness in advancing citizenship debates is in question. 
Indeed, there is a danger that it might act to obscure key debates which require urgent 
attention. The ‘bio’ part of biocitizenship is in constant danger of being given a 
reductive gloss, which has consequences for how citizenship issues are identified and 
approached. It is important to consider the danger that a notion of biocitizenship such 
as Rose and Novas’s might be co-opted to the service of biotechnology; why this is 
seen as problematic will be discussed. We end by posing the question of whether a 
notion of biocitizenship that fruitfully enhances democratic citizenship debate can be 
constructed. 
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The paper draws on qualitative ethnographic data collated between 2003 and 2006 
amongst UK publics engaging with human genetic/genomic technologies.2 
Ethnographic ‘snapshots’ were taken of emergent and multiple networks of publics 
engaging over a wide variety of issues, enabling a broad overview of key actors, 
claims (frames) and mobilisation patterns.3 Case study work focused in more detail 
amongst latent networks of actors predisposed to articulate oppositional frames,4 
exploring their emergent engagement with medical genetics/genomics.5 This co-
authored paper represents an interdisciplinary collaboration between social science 
and philosophy, with the intention of highlighting the relevance of some different 
bodies of academic thought to contemporary Science and Technology Studies (STS) 
debates on (bio)science, knowledge and public engagement. The notion of 
biocitizenship arises from long established debates around biopolitics, as well as the 
historical development of various conceptions of citizenship. Space does not permit a 
full examination of these issues, although they inform our critique of Rose and 
Novas’s explication of biocitizenship. There are many ways of approaching debates 
around citizenship; here we draw upon some key literature in some other academic 
disciplines, specifically from green politics, which we believe relates well to the 
debate on (bio)citizenship, and which, as we hope to show, provides one useful frame 
for illuminating some of the key problems with the concept as it currently stands. 
 
Current citizenship debates 
 
Contemporary accounts of, and debates about, the nature and the constituency of 
‘citizenship’ are of the Zeitgeist in a number of different academic domains, and are 
of course well established within STS, where they are linked to debates on expertise 
and knowledge production. (See, for example, Irwin,6 Irwin and Michael,7 and their 
discussions of ‘scientific citizens’ in particular.) In the sphere of ‘green politics’, 
theorists such as Fischer,8 Dobson,9 Barry 10 and Hayward 11 are engaging with the 
concept of citizenship, with the aim of firming up political theory for civil society 
environmental ‘best practice’ in an age of globalisation.12 They are debating concepts 
of emergent global ‘civil society’ engagement as a response to globalisation and the 
challenges of sustainable development, even as these social networks are evolving in 
real time.13 A recent debate in the journal Environmental Politics14 concerns Andrew 
Dobson’s conceptions of ecological citizenship, and whether they are a politically 
robust theoretical principle. Tim Hayward contends that Dobson’s concepts inform, 
rather than replace, a ‘traditional’ political conceptualisation of citizenship. Dobson, 
for his part, argues that the nature of politics, and of a political ‘polity’, ‘membership’ 
of which infers citizenship, need to be conceptualised beyond the confines of a nation-
state. Furthermore, he sees ecological citizenship as a practice, not a status. Tellingly 
for issues of inequality, which we argue are a major problem with biocitizenship, 
justice is a core principle of ecological citizenship for Dobson. Rights and duties of 
ecological citizenship are points of debate for both Hayward and Dobson. 
 
The existence and nature of the rights, duties and even membership of the category of 
citizen, is thus up for grabs not only within disciplines, but between them. There are 
multiple and overlapping citizenships, and there will inevitably be conflict and 
contest, as well as convergences, within and between citizenships. Therefore, we need 
to ask how much the label of ‘bio’ citizen adds to citizenship debates and to our 
understanding of our relationship to biotechnology. 
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Between them, ‘green’ political theorists like Barry, Hayward and Dobson have 
developed a conceptualisation of citizenship which, importantly, focuses on issues of 
social justice in an age of globalisation, where environmental risks, social inequities, 
and attendant health risks, are generally, but far from exclusively, borne by the global 
poor.15 Ecosystem and human health have comprised an explicit frame developed 
within the core concept of environmental sustainability and citizenship. Thus, the 
‘green’ environmental literature has made a significant contribution to the ‘red’ health 
literature, in terms of the clear links environmental theorists16 explicitly make 
between, for example, environmental degradation and pollution, and health,17 and also 
because, as Dobson argues in the pages of Environmental Politics, “justice is the 
virtue currency of ecological citizenship”.18 This literature examines in detail the key 
frames of environmental social justice–orientated health movements, such as those 
identified by Brown and Zavestoski.19 Such movements mobilise over health 
concerns, but consistently have accompanying core frames relating to social justice 
and environmental issues, for example over pollution grievances. 
 
In the 2004 special edition on health social movements in the journal Sociology of 
Health and Illness, the editors, Brown and Zavestoski, give several examples of such 
social movements, such as women’s health movements mobilising over breast 
cancer.20 Many other global examples exist, including locals questioning the 
‘coincidence’ of leukaemia clusters at Sellafield, ‘Love canal’ in the USA, and the 
mobilisation of Bhopal victims and their supporters. Tellingly, Rose and Novas offer 
the mobilisation of similar groups over the Chernobyl disaster as an example of how 
citizens understand themselves as biological citizens.21 To frame these mobilising 
actors as ‘biocitizens’ would be to emphasise one aspect of their identity. Brown and 
Zavestoski themselves emphasise that health is the core mobilising frame for several 
of these movements, but in truth the ‘bio’ prefix would mask the accompanying 
emphasis on social and environmental issues clearly foregrounded in much movement 
discourse. 
 
As we will argue, of the many different types of health groups and patient groups, 
biological identity will be a core mobilising factor (or issue to be identified with) for 
some, but not for others. Brown and Zavestoski themselves identify multiple 
typologies of health and patient groups that may conflict and overlap - the boundaries 
between identity types are blurred. It is perhaps a truism to state that all social actors 
as individuals consist of fluid and multiple identities, and that how one chooses to 
frame or present oneself, or how one is presented by others, is context-dependant. The 
notions of ‘biocitizens’ and/or ‘ecological citizens’ are crucial as there are important 
divergences in terms of emphasis, social construction, and potential solutions to 
identified problems, implied by the different prefixes. It is of concern to us that Rose 
and Novas, engaging with the spheres of health and medicine, are developing 
conceptions of biocitizenship in seeming isolation from the well developed debates on 
citizenship, justice and globalisation, which include debates on health and science, 
which have been occurring within ‘green’ political thought for some time. We argue 
that the types of issues raised by the ‘green’ literature illustrate core problems that we 
identify with Rose and Novas’s concept of biocitizenship. 
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Moreover, the rights and duties of any type of citizen are still going to be defined 
mostly by those with power; and they can consist of a variable and wide range. 
Through invoking a discourse of citizenship, and constructing contemporary 
meanings of it, Rose and Novas, Dobson, Barry et al are all engaging in important 
work in terms of identifying the need for greater civil society participation in all sorts 
of life practices, and championing those who do engage. However, conferring 
different types of rights, let alone duties, on civil society, which are invoked by 
concepts of citizenship, is extremely problematic when it comes to the policy 
definition of what these rights and duties are, and when their implications are 
examined in detail. In the context of medical health, the focus of this paper, various 
players in the public domain with specific ideological positions, such as outspoken 
bioethicists with broadly utilitarian agendas, and/or those with vested interests,22 are 
currently invoking the duties of citizenship; they are colonising a new arena of global 
civil society, using a discourse of citizenship to push a certain course of action before 
civil society has had a chance to even have a debate. For instance, John Harris has 
recently argued that “[b]iomedical research is so important that there is a positive 
moral obligation to pursue it and to participate in it”.23 We suggest that the urgency of 
debates around the construction of meaning make Jasanoff’s notion of ‘epistemic 
citizenship’ a more useful construct for articulating debates about the impact of 
biotechnology, a complex field where multiple struggles for meaning are being 




Rose and Novas make a general claim that “specific biological presuppositions, 
explicitly or implicitly, have underlain many citizenship projects, shaped conceptions 
of what it means to be a citizen, and underpinned distinctions between actual, 
potential, troublesome and impossible citizens”.25 They use ‘biocitizenship’ broadly, 
and descriptively, to “encompass all those citizenship projects that have linked their 
conceptions of citizens to beliefs about the biological existence of human beings, as 
individuals, as families and lineages, as communities, as population and races, and as 
a species.”26 Citizens may be ‘made up’ from above by governments’ particular 
practices that relate to corporeality or biology in some way. And biological notions, 
they argue, have in the past, and increasingly so, shaped citizens’ self-
understanding.27 
 
From this broad understanding they go on to explore how a notion of biocitizenship 
can be used to understand developing trends, such as their claim that “collectivities 
organised around specific biomedical classifications are increasingly significant”.28 
However, we consider that their explication of this concept, including the cast of the 
particular examples they use to illustrate it, means that their development of it 
incorporates clear normative implications, fostering particular relationships with 
biotechnology and potentially helping to forge new, and deepen existing, inequalities. 
It must be noted that they emphasise initially that “not all have equal citizenship in 
this new biological age”.29 Rose and Novas refer here specifically to problems with 
bioprospecting and biopiracy. In this paper we argue that many more examples of 
troubling inequality need scrutiny, and that many of Rose and Novas’s other examples 
act to divert attention away - with troubling implications - from inequalities sheltering 
under the roof of biocitizenship as they define and subsequently explicate it. 
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Questions of human value and human worth and biological responsibilities are played 
out in different ways in relation to biocitizenship. For Rose and Novas, this 
citizenship is inherently active, and they discuss biocitizenship in terms of ethical 
demands that biological senses of identification and affiliation enable, including 
rights, duties, responsibilities, prudence and choice. In fact, they claim, “judgments of 
value concerning certain features of bodies and capacities of citizens have become 
inescapable”.30 We go on critically to examine these ‘judgements of value’, giving 
some examples of how they are being constructed and apportioned to ‘biocitizens’, 
and demonstrating how the term ‘biocitizenship’, unless subjected to more critical 
engagement, could foster too sympathetic a reading of this process. The “distinctions 
between actual, potential, troublesome and impossible citizens” can be drawn and 
understood in many different ways. 
 
‘Making up’ biocitizens: Rose and Novas’s examples of patient groups 
 
Rose and Novas illustrate how biological categories are forming identities and 
groupings for activism and for ‘making up’ categories of citizens in relation to the 
authorities with the use of various examples. We begin our critique with an 
examination of those examples, enriching the sample from our own ethnographic data, 
and showing how their ethnographic examples act to skew the biocitizenship agenda. 
This is largely due to the fact that they do not emphasise sufficiently that their data 
primarily represent a certain type of ‘biocitizen’ and fail to identify the range of other 
emergent groups and networks exercising citizenship stakes in this arena. 
 
Following on from this, careful examination of Rose and Novas’s use of the term 
‘biological’, and the way in which identities of various groupings are formed, leads us 
to see that, in this context, to prioritise the biological is often ipso facto to produce a 
reductive account of problems, solutions and identities.31 This potential reductionism 
may seduce us into a narrow outlook; at the same time, the ‘biological’ label can be 
applied very widely to a host of divergent issues and divergent understandings to the 
extent that it obscures salient distinctions and real disputes over goals and values, and 
hinders our ability to think critically and robustly about the impact of biotechnology 
on humanity. As we shall argue, Rose and Novas tend to identify as biological certain 
membership categories even though the rejection of biology is a salient organising 
feature for some, and select examples of mobilisation which reinforce the ‘future 
promise’32 framing of biotechnology rather than ones which seek to critique and 
curtail it. 
 
Moreover, they locate the patient groups to which they refer as examples of 
‘informational biocitizenship’, involving specific scientific and medical knowledge of 
one’s condition.33 However, there is a grave danger that this might overlook real 
issues and disputes about the veracity and salience of this ‘scientific and medical 
knowledge’. Thus, we argue, the way in which Rose and Novas have so far explicated 
the idea of biocitizenship acts to present it in a certain, implicitly favourable, relation 
to biotechnology industry and biotechnological knowledge. It remains to be seen 
whether some notion of biocitizenship might be possible which leaves more space for 
open debates about the directions and benefits of biotechnology. Such debates on the 
nature and implications of the ‘bio-economy’ incorporate other familiar issues such as 
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expertise, how knowledges are defined and found to be of value. As we will 
demonstrate, these are core themes within many civil society groups and networks 
whose voices are often misheard, if they are heard at all.  Such issues are, to reiterate, 
well debated within the breadth of ‘citizenship’ literature highlighted earlier. 
 
Thus the multiple debates in the context of bioscience and health consistently 
highlight how different actors construct multiple meanings of words (self, health, 
choice, rights, knowledge etc) and how certain words come to be used in the first 
place. To reiterate, by grappling with the nature of knowledge and the values 
trajectories, which different meanings (ie. different knowledge bases) provide, 
Jasanoff’s conceptualisation of ‘epistemic citizenship’ could be understood to be of 
perfect relevance for global civil society’s engagement with bio-science in the 
‘knowledge economy’. 
 
Rose and Novas draw on certain key examples of the empowered, informed patient-
as-consumer (group, network, etc) - an engaged, mobilising actor in the bioeconomy 
and engaging with health issues and bioscience. There is no doubt that this is an 
important emergent social reality. Likewise, Brown and Zavestoski delineate various 
cross-cutting types of ‘health social movement’, from ‘embodied health movements’ 
seeking to assert their own ‘embodied expertise’ in relation to their own disease 
status, to what they term ‘constituency-based health movements’ focusing more on 
equity and access issues.34 
 
Rose and Novas discuss what they call the “proliferation of biosocial communities”, 
such as those mobilising around manic depression. But tellingly, this particular form 
of depression is one for which a biological origin is more strongly accepted than is the 
case with other forms. Their discussion of the Prozac website35 talks of how it fosters 
an active aspect of biological citizenship. Many pharmaceutical companies have 
strong links with patient groups; websites often contain links to these. But these links 
are to patient groups that tend to lobby for greater access to drugs and to 
pharmaceutical based research. The Prozac website does not give links to patient 
groups mobilising around litigation concerning alleged adverse effects of Prozac or of 
its alleged overprescription (eg, Prozac Survivor).36,37 Moreover, a recent report by 
Consumers International criticises drug companies for misleading consumers, and 
cites the sponsoring of patient groups funding disease awareness campaigns as a new 
technique in their armoury of marketing strategies.38,39 
 
Crucially for questions of the labelling of ‘bio’ citizenship, many such patient groups 
consider alternatives to biological accounts of depression. Additionally, the very 
disease categories around which identity categories may coalesce or emerge 
themselves come under scrutiny. As one example of how new biological languages 
are ‘making up citizens’, Rose and Novas cite the woman with pre-menstrual 
dysphoric disorder. But there are those who question the construction of this very 
disorder, and, it is worth saying, many other disorders, especially psychiatric ones.40 
This is to say more than simply that such disorders are social constructions; it is to 
question the power base of such constructions. Such concerns were raised by some of 
our interviewees: 
 
‘[W]e have good evidence of them inventing symptoms…The one 
which always comes to mind is female sexual dysfunction…they 
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[pharmaceutical companies] have this way of saying that actually we 
can cure that.  Well, there might be some aspect of that but…in fact 
we have a whole literature that’s been generated by the 
pharmaceutical companies…saying we now have this thing called 
female sexual dysfunction and if you’re not having sex and enjoying 
it well, you need to have our pills that we’re offering you.’ 
‘Mike’, technology campaigner in interview, 2004 
 
The persistence of pre-menstrual dysphoric disorder as a category is arguably at least 
in part due to marketing strategies formulated by Eli Lilly in response to patent law, 
and designed to bypass the lapse of the patent on Prozac by re-licensing it for a new 
application under the brand name of Sarafem.41 Utterly crucial to the labelling of 
actions as ‘biocitizenship’, is pre-menstrual dysphoric disorder then a biological 
category, or an economic and legal category?42 To encompass this citizenship 
behaviour under the banner ‘biological’ is to bypass this complexity, and to miss the 
many layers of meaning – biological, social, psychological, economic, legal, and so 
on – that can inform the frequently contested multiple and shifting identities of 
various citizenship projects. The reductionist focus on the biological may act to 
obscure the economic and other forces at play. In turn, it may then act to obscure the 
power flows that help to make up categories as biological or otherwise, and hence 
help to influence strategies for action. 
 
Crucially, with regard to citizenship, there is a world of difference between citizens 
freely mobilising in relation to biotechnology, and ‘citizens’ actually being 
manipulated by the giants of biotechnology to their own ends of increasing their 
economic and commercial power. To posit both behaviours under the label of 
biocitizenship is arguably to render the term so loose that it is of scant use in 
illuminating citizenship behaviours and debates. Any use of the ‘bio’ label must be 
such that it does not obscure such important issues of the flow of power. 
 
This is further illustrated in the fact that, crucially, examples Rose and Novas use tend 
to be ones where ‘biocitizens’ are mobilising over their own health and bodies, 
identifying themselves as part of ‘disease communities’ concerned about access, 
price, quality and availability of treatments and cures - in other words, over increasing 
access to the fruits of biotechnology. As Brown and Zavestoski highlight, such 
personal motivations are often - but not always - tied into social and political critiques 
as regards social equity and access. Rose and Novas refer to groups such as those 
mobilising around AIDS, which aim to increase access to drugs, and PXE, which are 
concerned with ‘open source’ issues and accelerating research.43 Similarly, in Seoul in 
February 2003, activists occupied Novartis head office in order to protest about the 
high cost of the anti-sarcoma drug Glivec.44 These examples are (at least relative) 
success stories, and the happy marriage of (even occasionally troublesome) patient 
group and biotechnology corporations helps to bolster claims that the citizenship 
activities are rightly seen as biological citizenship. 
 
However there are many other mobilising actors whose putative ‘biocitizenship’ 
seems markedly less valid; boundaries can start to blur and conflict when issues of 
social justice, political economy and environment become more dominant than the 
discourse of medical and pharmaceutical cures. Even in Rose and Novas’s own 
examples, one can question the usefulness of foregrounding the ‘bio’ in 
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biocitizenship. The protests over drug access are having an impact on global 
governance, demonstrated by recent changes to the WTO rules intended to enable the 
supply of generic copies of branded drugs.45 It is essential to emphasise the 
importance of social justice and anti-globalisation critiques here within the broader 
frame of health. For instance, the People’s Health Movement46 focuses predominantly 
on the social, political and economic aspects of health problems and their solutions, 
and strongly attacks globalisation’s role in health crises, identifying the role of 
poverty as a killer and threat to health of epidemic proportions. This focus does not 
deny a role for medical cures but still bases its mobilisation over health on core issues 
of social and environmental injustice and exploitation.47 Indeed such discourses also 
touch policy. WHO and UNESCO have strongly advanced calls for global equity as 
the basis for global health, and a 2005 WHO report has critiqued genetic hype in 
relation to third world health outcomes.48 This example clearly shows the exercising 
of citizenship via a different route to that of the pro-pharmaco patient citizen. 
 
We can see, therefore, that distilling out the biological (through an appellation of 
biocitizenship) may give a reductive, narrow account of the activities of citizens. 
Moreover there are also those who actively seek to criticise, oppose or rein in the 
activities of biotechnology - those who consider certain drugs to be too readily 
available, for example. Are these kinds of activity usefully grouped under the 
umbrella of biocitizenship? In considering this, it is telling that this civil society path 
is often far less politically successful. To give one example, the odds tend to be 
stacked against those pursuing legal claims against pharmaceutical companies, 
especially for class actions.49 Lately, following failed action relating to Vioxx, fears 
have been expressed that such litigation can no longer be undertaken in the UK.50 
 
It would appear therefore, that some types of biocitizens - if we are to use the term at 
all – have more legitimacy and more airtime than others. Moreover, these groups’ 
aims of reining in biotechnology make the label of ‘biocitizenship’ one that 
encompasses ‘strange bedfellows’,51 who would often find themselves on quite 
different sides of the fence with regard to the benefits of biotechnology. This is a 
crucial point, for in discussing the alleged responsibilities and duties of biocitizens, as 
we go on to do, we must expose and articulate the goals and values that lie behind any 
such claims. 
 
Biocitizenship is a broad term, allegedly, that can encompass opposition.52 But there 
are indications that its reductive focus on the biological may act actually to obscure 
debates and issues that need to be heard. We go on to explicate these points in more 
detail. 
 
Citizenship, reductionism and ‘bio’ labelling 
 
It is crucial to recognise that issues of identity, biological or otherwise (eg, 
encompassing values, or notions of community) are far more problematic than Rose 
and Novas seemingly allow for in their use of the label ‘biocitizen’. This then prompts 
us to ask the question of whether such a large degree of conflict can be helpfully 
captured within the domain of the term ‘biocitizenship’. Whilst conflict between 
different positions is of the essence of different citizenship claims, if Rose and 
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Novas’s explication of biocitizenship does not expose this conflict, this is a serious 
shortcoming. 
 
As this paper will discuss, the construction, maintenance and defence of identity is 
complex and, in relation to biology, problematic.53 Over-using or over-privileging the 
‘bio’ prefix is problematic, since a core criticism of the whole bioscience project from 
many different directions is the geneticisation and medicalisation of what are arguably 
social, and often normative, constructs and social issues. Similarly there are good 
reasons why the ‘bio-labelling’ of identity is reductionist, and possibly even racist, 
feeding into the dominance of genetic explanations of self, identity and ‘human 
nature’. Thus, much critical discourse around ‘biosubjectivities’ concerns precisely 
this point: the rejection of the ‘bio’ label in favour of social explanations and 
solutions. 
 
That said, in many ways genetic ‘information’ is impacting the identity/cultural 
sphere as groups and communities respond in various ways to genetic ‘meanings’, 
embracing or rejecting them, sometimes both at once. In this sense it is important to 
think about the ‘bio’ in biocitizens, in the sense that many people, in many ways, are 
mobilising over issues relating to biology in one form or another. But as we have 
seen, choosing the ‘bio’ label as the primary frame for any identity group is 
problematic with regard to the other issues that it helps to obscure. Moreover, as is 
already indicated and as we go on to discuss in detail, a myriad problems with 
equality arise within the biological. Grounding citizenship on our biology, without 
other considerations or safeguards, is inherently elitist, as there is simply no way of 
articulating criteria of inclusion that ground equal citizenship to all. We will argue 
that biocitizenship as articulated by Rose and Novas acts to obscure important issues 
about equality that urgently need attention. 
 
Disability rights provide a clear example of identity fragmentation in this context. 
Someone diagnosed with a specific syndrome could identify themselves as a member 
of a patient group wanting cures or as a member of a disability rights group 
mobilising over access to treatments and a range of social provision. Such an 
individual could see their syndrome as core to their identity, or could reject the 
centrality of a biologically informed construction of their own identity. They may 
hold, or feel strongly antagonistic to some of these positions, and/or ambivalent about 
some or all of them. The core issue here is to recognise the complexity and 
ambivalence surrounding any construction of identity and related citizenships, 
because identities are multiple and also fluid. To depict even one individual, much 
less an entire ‘disease community’ or our entire species as ‘biocitizens’, is to 
unhelpfully and unnecessarily reify a complex debate. It is because of the fragmented, 
complex and often contradictory nature of any individual’s identity, not to mention 
the well-identified difficulties within the concept of ‘collective identity’54 in terms of 
what a social movement is,55 that definitions of civil society engagement with issues 
of biology, bodies and identity are so problematic. The complex identity politics in the 
health sphere identified above highlight why the construction of identity is an ongoing 
problem for social movement theorists.56 
 
Rose and Novas’s notion of biological citizenship is formulated against a historical 
backdrop of various citizenship claims that make some reference to biology. These 
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various claims act to make the question of biology a key frame through which to view 
questions of citizenship. But looking at the history of citizenship from a different 
angle, we might see that a key frame for forming citizenship projects is the 
recognition of biology as highly problematic and potentially divisive, or indeed, as 
something to be rejected entirely. This is most obvious, perhaps, in the citizenship of 
women. 
 
A brief overview only is possible here. But it will serve our purpose of questioning 
whether simply raising the issue of biology is enough for the label ‘biocitizen’, or 
whether the rejection of biology as a politically organising concept means the ‘bio’ 
label is otiose. Mary Wollstonecraft famously argued for an extension of citizenship 
rights to women on the basis of a shared reason with men,57 and J. S. Mill followed 
her in sidelining the issue of biology.58 The liberal feminism that developed from 
these roots came to recognise that obscuring biology entirely might do women a 
disservice, and other feminisms have given biology quite a different place. Feminist 
views have ranged from those who wish to celebrate the uniqueness of female 
biology, to those who wish to minimise its significance, to those who wish to harness 
technology and change social structures to mould female biology. What the history of 
feminist thought does do though, is forcibly remind us that biology is a contested and 
problematic notion, not least in relation to issues of equality or inequality of citizens.59 
Insofar as women have been citizens, they have always been biological citizens in the 
sense that their biology has been addressed in one way or another. Yet this label tells 
little of the struggles with biology that mark different feminisms’ attempts to grapple 
with concrete and theoretical issues of inequality. A simple notion of ‘biological 
citizenship’ is in danger of obscuring, rather than stimulating many important debates. 
 
Biocitizenship and its values 
 
In considering the articulation of the notion of biocitizenship and its potential value, it 
is important to consider how a notion of biocitizenship might be co-opted in relation 
to various key citizenship debates, including the question of what responsibilities in 
relation to biotechnology are owed by the altruistic biocitizen. It is important to be 
clear that in discussing various claims that may be being made about such 
responsibilities, we are not necessarily suggesting that Rose and Novas themselves 
share these claims. Rather, our aim is to consider how their notion of biocitizenship, 
unless defined more robustly, might potentially be drawn upon in ways they might not 
intend. Our prime concern is that their notion of biocitizenship might act uncritically 
to foster the industrial and economic ambitions of biotechnology, despite their 
attention to issues surrounding ‘biopiracy’.60 
 
Talk of responsibilities of the biocitizen in relation to developments in biotechnology 
in particular has to be viewed against the backdrop of current considerations of 
responsibilities in relation to health care in general. These are present in various 
forms, some implicit, others overt.61,62 The general thrust of these accounts of 
responsibility, whilst paying some attention to systemic and organisational origins of 
health problems, such as the recent UK school dinners debate,63 is to encourage 
individuals and communities within a larger society to take on greater responsibility 
for health. Questions about citizenship entitlements and duties are pressing in these 
debates, and bring to the fore the issues of equality and fairness.64 
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Only some of the responsibilities of citizens, such as responsibilities to obey the law, 
and, in some jurisdictions, positive responsibilities such as the duty to vote, are clearly 
delineated. Others are more loosely articulated, and may not apply to all depending on 
one’s situation in life and varying social circumstances. What is important to consider 
is how such duties are constructed, and exactly how citizens are exhorted to various 
responsibilities and acts of altruism. It is important to be clear how notions of 
altruism, duties, and responsibility are linked to an underlying framework of values 
and goals. An action can only be a duty, a responsibility, or altruistic if it carries a 
benefit. But benefits are disputed, and benefits in relation to medicine and 
biotechnology are no exception. We need to consider whether a notion of 
biocitizenship might channel the vision towards certain kinds of putative benefit and 
away from others. We also need to consider who is benefiting, and upon which 
citizens any associated burdens fall. Notions of citizenship do not in themselves imply 
equality; however, in examining the potentially problematic implications of Rose and 
Novas’s account of biocitizenship, a key issue is whether this notion itself might act to 
exacerbate the unequal spread of such benefit and burden. 
 
Following Raynor Rapp,65 Rose and Novas see new biosocial communities as ‘moral 
pioneers’ re-imagining those to whom they owe responsibility. But they also make 
specific claims about this: they state, for instance, that “[t]he responsibility for the self 
now implicates both ‘corporeal’ and ‘genetic’ responsibility…now one must also 
know and manage the implications of one’s own genome.”66 It has been argued 
explicitly by others that we may even have a ‘moral duty’ to genetically enhance our 
children.67,68 And, as mentioned earlier, taking part in biomedical research is, 
arguably, itself a duty.69 This may include donating to biobanks, donating surplus ova 
and embryos following IVF treatment, and donating ova ‘altruistically’ for the 
specific purposes of research into so-called ‘therapeutic’ cloning.70 Feminist and 
social justice academics and campaigners have been quick to critique the ‘gift’ and 
‘duty’ discourse attached to the issue of ‘altruistic’ egg donation for cloning, for 
example,71,72 and to highlight the medical risks to women.73,74 
 
Moral pioneers and others must exercise care when they attempt to describe new 
responsibilities. For instance, there are many reasons for caution in relation to calls to 
take part in medical research. A core issue is the risks of these duties. The (unequally 
distributed, and disputed) risks and burdens on individuals are, or should be, taken 
into account in assigning duties. Also necessary is a clear and accurate analysis of 
how a particular, alleged duty is needed to accomplish the (unequally distributed, and 
disputed) goals identified from the framework of values. As we shall see, in 
discussions of biotechnology, these issues are frequently problematic. Alternative 
views of values and goals, ends and means, may undermine alleged duties of 
biocitizens. Here the ‘green’ citizenship debates outlined earlier (eg, by Barry and 
Dobson75) are crucial to getting a fix on what is at stake here; the importance of 
incorporating debates on social justice and sustainability. 
 
Biocitizenship and the political economy of research  
 
One important consideration stems from the ‘political economy of research’. The 
financial and other influences on people’s decisions to offer themselves up as research 
subjects or as sources of biological material can call into question the notion of 
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informed consent and indeed the notion of altruism, for altruism requires some degree 
of purity of motive, for public good, which is seriously muddied by the financial 
interests both of the biotechnology industry and of certain public ‘volunteers’.76 
Concerns about the goals of biotechnology will cast radical doubt upon its legitimacy 
to set out a vision of altruism for the ‘biological citizen’: 
 
‘The pharmaco industry is…looking at the new ways to extend their 
profits through their innovations, and the fact that it’s led very much 
by that is a warning sign…It’s a redefinition of what is healthy. And 
if you have an ongoing redefinition of normal…suddenly we will 
become unhealthy and with defects…we all then therefore become a 
market for improving ourselves.’ 
‘Mike’ in interview 2004 
 
‘I don’t like the idea that by volunteering public-spiritedly…Glaxo-
Wellcome could end up owning the patent on my cell line which poor 
people have to pay for.’ 
Member of ‘disease community’ in genetics workshop, European 
Social Forum, London, October 2004 
 
Concerns about the relationship of research to the market cast doubt on who is really 
being served by advances in biotechnology. The biocitizen-as-consumer fits with the 
dominant discourse of biotechnology competitiveness77 in the EU ‘knowledge 
economy’: 
 
‘knowledge lies at the heart of the European Union's Lisbon Strategy 
to become the “most dynamic competitive knowledge-based economy 
in the world”.’78 
 
The programme specifically favours scientific knowledge production, in particular 
nanotechnology and biotechnology, exemplified via the budget expenditure for 
FP6/FP7.79 The emergence and implications of  ‘the Bioeconomy’ has increasingly 
become the focus of academic debates,80 raising issues such as whether the Neoliberal 
project of the bioeconomy will solve, or exacerbate, issues of social exclusion, 
injustice, and environmental risk; to reiterate, issues also raised in other contexts by 
the green politics literature. We have shown that many of the engaged civil society 
actors critique the EU ‘big science’ knowledge economy agenda in very clear terms: 
 
‘Such an approach supports and judges research and innovation 
only in its ability to deliver moneymaking ventures, not whether it 




What is the real motivation behind those who are setting agendas and values in 
relation to biocitizenship? Are we really being asked to do something altruistic or are 
we serving mammon and fostering dominant cultural values? 
 
‘[T]he reason the [TGN1412] trial82 was happening in the UK first 
was probably because the UK establishment, though good by global 
standards, saw granting swift go/no go trial decisions as important 
for UK competitiveness in a field in which the UK is perceived as 
having a comparative advantage…’ 
Industry ‘insider’ in personal email, 25 April 2006 
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The limited cast of Rose and Novas’s examples, and the reductionist skew to their 
account, indeed the very focus on biology served by the ‘bio’ prefix, could all be 
argued to act tacitly to allow the interests of the market forces of biotechnology to 
operate by stealth. Citizens may not then be served well by focus on the biological if it 
closes down the space to frame and debate other issues and challenge implicit 
meanings and values - the very construction of disease, for example. 
 
Biocitizenship and notions of ‘progress’ 
 
These points alert us that notions of ‘progress’ behind research may be questioned. 
This questioning may be viewed as ‘anti-progress’, but more commonly and more 
accurately, it may rest upon different notions of what constitutes progress. For 
example, there have been a number of critiques of the notion of human 
‘enhancement’.83,84 ,85 It is also noteworthy that early applications of some of this 
technology are for purposes which are cosmetic, commercially motivated and quite 
clearly, culturally loaded, and with clear gender issues. Recent media reports of the 
‘future promise’86 of the use of stem cells have included their use for ‘safe’ cosmetic 
breast ‘enhancement’.87 Is it a coincidence that one of first commercial uses of 
nanotech is for anti-ageing face creams (L’Oreal)?88,89 Can ‘duties’ and 
‘responsibilities’ to take part in ‘cutting edge’ research (eg, egg ‘donation’ for stem 
cells) possibly refer to such end-of-pipe applications and outcomes, the direction of 
which are dictated by ‘lowest common denominator’ cultural pressures and market 
flows? 
 
Critiques based on medicalisation and geneticisation cast doubt upon the rationale and 
deleterious effects of progress cashed out in narrowly biotechnological terms: 
 
‘[M]y life in the last two years has been a hundred percent better 
because I’ve been in housing which meets my needs and it’s 
something as simple as being on the ground floor…we need society 
to accept diversity, it can’t rely on us changing…they’re spending 
huge wads of money on things, when they could be fixing the day to 
day problems of people that have all sorts of conditions by spending 
that money elsewhere.’ 
‘Sally’ Disability Rights activist in interview 2004 
 
Focus on constructions of biocitizenship where the dominant construction of health is 
the medical fix, influences discourses of progress. But if the STS/bioethics debate 
were set more broadly in relation to citizenship and health, as it is in other academic 
and civil society arenas as we have argued, other issues arise concerning the 
construction of health, and how we can be healthy.90 What would a focus on 
biocitizenship - as opposed to, say, health-citizenship - achieve for these urgently-
needed debates? 
 
Biocitizenship, duties and ‘choices’ 
 
These issues can be seen further in the many problematic examples of how putative 
‘goods’ are presented to putative biocitizens. Among these are what we might term 
‘crypto-duties’ masquerading as choices. Pregnant women carry a disproportionate 
social burden here. One could argue that the context of prenatal testing, whilst overtly 
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about ‘informed’ choice, contains various pressures towards accepting the embryonic 
screening tests offered them and aborting or not implanting the ‘defective’ foetus. 
What is certain is that these are difficult decisions; parents, and specifically women, 
may well be under pressure to ‘do the right thing by society’. There are also seeming 
duties of biocitizenship that we cannot escape and which many have railed against. In 
the ‘lab without walls’91 we are all subject to unquantifiable (medical and 
environmental) risk92 from bio-experiments such as GM crops, viral vectors, 
genetically-modified superviruses and nano-particles).93,94 We all face being subject 
to increasing biosurveillance in the name of security, in the form of forensic DNA 
databanks, biometric scans for passports, and nanotechnological military applications 
such as ‘smart dust’.95 
 
Rose and Novas acknowledge that governments will ‘make up’ biological citizens in 
ways imposed from above, but we question if their discussion and development of the 
concept of biocitizenship is sufficiently critical robustly to identify problems with the 
way bioscience is currently ‘making up citizenship’. Biocitizenship needs to grapple 
head on with the issues of what, or how much free choice we should be allowed, and 
what we can legitimately be encouraged or even coerced into accepting. Currently, 
biocitizenship implies that certain citizenship outcomes (rights, choices, duties, goals 
etc) have value, whilst by their absence from the debate, it is implied that others do 
not. 
 
Biocitizenship and the construction and entrenchment of inequalities 
 
As Rose and Novas say, “not all have equal citizenship in this new biological age”.96 
However, we consider that the question of inequalities needs to be foregrounded much 
more clearly than is apparent from Rose and Novas’s explication of biocitizenship. 
Indeed, this ‘new biological age’ is in danger of actually increasing existing 
inequalities and inventing new ones. Rather than simply describing social phenomena, 
biocitizenship may act itself as a force acting to increase biologically- and 
technologically-conditioned inequalities. 
 
There are many troubling examples of such inequalities in operation. In research 
conducted between 2003 and 2006 on UK public engagement with medical genetics,97 
one of the core issues for many different groups of publics was the multiple 
complexities, anxieties and ambiguities around the issue of embryonic screening. In 
the same time period, several important public policy consultations on this topic have 
been launched.98,99,100 Research data from the ‘Emerging Politics’ project101 shows 
clearly that even when individual members of the public are generally supportive of 
the genetic testing of embryos (and many are not), they also voice concern and 
acknowledge deep, and often simultaneously contradictory, complexities, beyond our 
current remit. But these include the almost universal acknowledgement that these are 
difficult decisions and that women of childbearing age are on the front line of bearing 
this ‘burden of choice’. 
 
Controversially, prior to the outcome of a public consultation on the issue,102 the UK 
HFEA has recently amended a license to ‘allow’ women to donate ova ‘altruistically’ 
for medical research,103 and this practice already occurs elsewhere.104 Major 
biological differences in the ease of gamete donation between the sexes exist, and 
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unless this is clearly recognised, there is a danger of unequal burdens being placed on 
certain (ie, female) biocitizens.105 This is especially pertinent given that women are 
already placed at disproportionate medical risk by having been excluded from much 
medical research where women, as individuals or as a class, could benefit.106 
 
These and other possible examples of inequalities demonstrate that questions of unfair 
burden and benefit are pressing. It is vital that any useful notion of biocitizenship 
allows for full expression of these debates. Insofar as Rose and Novas’s account acts 
to valorise biotechnology, even if inadvertently so, such important citizenship 
discussions will be hindered rather than eased. 
 
Inequalities may also be created or entrenched because a certain type of patient group 
has much ‘discursive legitimacy’ with their core frames of cures, hope and 
progress.107 Their citizenship involves critique of current practice, but the fact that 
they mobilise over ‘cures’ acts to support the frames and agendas of the dominant 
paradigm generally supportive of biotechnology and of its industry. In contrast, 
critical or oppositional biosubjects and biosubjectivities who see themselves as under 
threat in some way from biotechnology have very little discursive legitimacy in the 
brave new ‘future promise’108 world of cures and enhancement for all. 
 
Disability Rights (DR) groups and radical feminists critical of ‘enhancement’ and of 
the implications of (embryonic) genetic screening and testing are rarely heard voices 
in the biosciences/bioethics debates, even when ‘big hitters’ like Habermas are also 
concerned about ‘market-led eugenics’.109 Bioscience can be seen as another means 
through which power relations, and capitalism as a form of power relation, gets a 
market out of the Western rich and ‘the worried well’ at the expense of the poor and 
marginalised. If such critical voices are indeed ‘biocitizens’, it is in a very different 
way to how patient groups, who, for example, benefit from financial support from the 
pharmaceutical industry, are biocitizens. 
 
‘[A]nd I’ve seen the presentation saying “Here is your market in the 
coming fifty years.” Well, you’ve got an aging population - baby 
boomers who are into staying young…and they don’t want to get 
Alzheimer’s…which makes sense financially…It’s a very clever 
strategy but it doesn’t do anything for the poor, it doesn’t do 
anything for the disabled and makes them even more beyond the 
pale, which is the wrong approach - it’s the medicalised approach 
rather than a society approach and [it] doesn’t do anything for the 
most vulnerable in society. Apart from that it will perhaps make 
them feel even less part of society because they’re even more 
defective.’ 
‘Mike’ in interview, 2004 
 
‘Mike’ is here concerned that certain, market-defined groups will benefit 
disproportionately from biotechnological developments. There are many reasons to 
think that ‘the poor’ as a group suffer disproportionate burdens and receive scant 
benefit from developments in biotechnology.110 
 
Many of these concerns about inequality and access are taken up by ‘New Chartists’. 
Their concerns include the lack of public engagement in agenda setting,111 
unquantifiable risk/uncertainty in the domains of health and the environment, and the 
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notion of ‘enclosures’,112 exemplified in concerns over ‘biopiracy’ and 
‘biocolonialism’. Issues of ownership and commodification of ‘life’ and of ‘the 
human’, are taken up, together with concerns about (bio)surveillance and control. 
These ‘New Chartists’ are very unlikely to be given credence as legitimate players in 
terms of polity/policy and they are certainly not the type of biocitizens that Rose and 
Novas have in mind at all.113 In fact, as we have argued throughout, the notion of 
biocitizenship seems set up to exclude the already marginalised views of such 




Our argument has been in part empirical and in part methodological: we have shown 
ways in which the notion of biocitizenship articulated by Rose and Novas is 
explicated by reference to a limited range of examples, and based on an uncritically 
reductionist framework. This in turn carries the danger, albeit unintended, of an overly 
uncritical relationship with developments in biotechnology. Bioscience is certainly 
‘making up citizens’ – this is an important emergent social reality - but Rose and 
Novas are constructing this far too optimistically. Our discussion of additional 
examples of citizenship, together with the use of notions, and implications, of 
citizenship from green politics, brings a fresh and, we hope, illuminating cast to the 
debate. We need now to ask if a notion of biocitizenship which overcomes these 
shortcomings could be articulated. Examining an idea of biocitizenship, if done 
critically, actually alerts us to the ways in which we are not all equal in relation to 
biology and to biotechnology, and to all reasons why we are subject to biotechnology 
rather than active citizens staking out a claim on it. Can a robust notion of 
biocitizenship be developed which allows room for debate and divergence, or does the 
‘bio’ label inevitably act to tunnel our vision? 
 
We should beware the bio-labelling of complex identities. Rather than there being a 
blanket biocitizenship, multiple publics are contesting power relations in multiple 
arenas. The many citizens identified here who are engaging, often passionately, in 
many different ways with these issues are certainly exercising what several key 
thinkers in this field have identified as important aspects of global citizenship.114 They 
are exercising what Dryzek has termed ‘discursive turns’.115 Such ‘discursive turns’ 
need to be heard sensitively to enable conflicting claims and ambivalences full scope, 
and the debating stakes set as broadly and openly as possible. Otherwise, in terms of 
thinking about public engagement with bioscience, without urgent debate, 
‘biocitizenship’ could become a co-opted term. Citizenship, as we said at the start, is 
now common currency, especially for thinking about concepts of ‘global civil 
society’. However, as we have shown, civil society engagement with bioscience 
reflects widely different knowledge claims and different stakes on the construction of 
meaning as they exercise multiple expressions of ‘epistemic citizenship’. 
 
Whilst it must be recognised that we all inhabit multiple citizenships, the muddling of 
multiple identities behind the ‘bio’ prefix, which acts to obscure potential forms of 
citizenship engagement and to channel problems and their solutions in certain 
directions, means ultimately that any notion of biocitizenship is likely to foreground 
reductionist accounts. Thus, rather than simply describing a space within which a kind 
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of citizenship can be articulated, it is liable to mould the kinds of thoughts and actions 
that can take place within that space. 
 
It is time for us, as academics also engaged in constructing meanings, (see also John 
Law for an account of how research methods are always political)116 to start taking 
our own ‘epistemic citizenship’ somewhat more seriously. 
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